Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?Sharyn D Baker, Alex Sparreboom
Bio-Protocol|March 23, 2019
Hypoxia Reporter Element AssayDaelynn R Buelow, Sharyn D Baker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?Alex Sparreboom, Sharyn D Baker, Jaap Verweij
Clinical Pharmacokinetics|March 3, 2006
Clinical pharmacokinetics of docetaxel : recent developmentsSharyn D Baker, Alex Sparreboom, Jaap Verweij
Clinical Pharmacology and Therapeutics|August 11, 2017
Kinase Inhibitors: The Reality Behind the SuccessJae Yoon Jeon, Alex Sparreboom, Sharyn D Baker
Basic & Clinical Pharmacology & Toxicology|June 12, 2021
Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactionsEric D Eisenmann, Zahra Talebi, Alex Sparreboom, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 14, 2023
Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MSZahra Talebi, Yan Jin, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymesJing Li, Ming Zhao, Ping He, et al.
Investigational New Drugs|February 28, 2006
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patientsJing Li, Julie Brahmer, Wells Messersmith, et al.
Anti-Cancer Drugs|June 5, 2003
Distribution of paclitaxel in plasma and cerebrospinal fluidHans Gelderblom, Sharyn D Baker, Ming Zhao, et al.
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?Sharyn D Baker, Alex Sparreboom
Bio-Protocol|March 23, 2019
Hypoxia Reporter Element AssayDaelynn R Buelow, Sharyn D Baker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?Alex Sparreboom, Sharyn D Baker, Jaap Verweij
Clinical Pharmacokinetics|March 3, 2006
Clinical pharmacokinetics of docetaxel : recent developmentsSharyn D Baker, Alex Sparreboom, Jaap Verweij
Clinical Pharmacology and Therapeutics|August 11, 2017
Kinase Inhibitors: The Reality Behind the SuccessJae Yoon Jeon, Alex Sparreboom, Sharyn D Baker
Basic & Clinical Pharmacology & Toxicology|June 12, 2021
Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactionsEric D Eisenmann, Zahra Talebi, Alex Sparreboom, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 14, 2023
Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MSZahra Talebi, Yan Jin, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymesJing Li, Ming Zhao, Ping He, et al.
Investigational New Drugs|February 28, 2006
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patientsJing Li, Julie Brahmer, Wells Messersmith, et al.
Anti-Cancer Drugs|June 5, 2003
Distribution of paclitaxel in plasma and cerebrospinal fluidHans Gelderblom, Sharyn D Baker, Ming Zhao, et al.
Pageof 17